Table 2.

Phase 2 studies of PTX-based preoperative neoadjuvant chemoradiotherapy for EC patients

Authors	Cases (SC/AC/other)	Chemotherapy	Radiation dose (Gy)	Median survival (months)	pCR
					Total	SC	AC
Safran, et al. [26]	41 (12/29)	PTX 60 mg/m2 3 h; DDP 25 mg/m2 d1, 8, 15, 22	39.6	15	29%	42%	24%
Bains, et al. [27]	41 (16/25)	Induction, DDP 75 mg/m2; PTX 175 mg/m2, W 1, 4; Concurrent, DDP 30 mg/m2/w; PTX 30–80 mg/m2/w, 96 h civ w 7–12	50.4	–	22%	31%	16%
Urba, et al. [28]	69 (10/57/2)	DDP 75 mg/m2 d1; PTX 60 mg/m2 d1, 8, 15, 22	45	24	19%	–	–
Van Meerten, et al. [29]	54 (12/41/1)	PTX 50 mg/m2, d1, 8, 15, 22, 29; CBP AUC = 2, d1, 8, 15, 22, 29	41.4	–	25%	–	–
Meluch, et al. [30]	129 (35/91/3)	PTX 200 mg/m2, 1 h, d1, 22; CBP AUC = 4, d1, 22; 5-FU 225 mg/m2/d, civ, d1–42	45	22	38%	53%	37%
Lin, et al. [31]	97 (92/5)	PTX 35 mg/m2, 1 h, d1, d4; DDP 15 mg/m2 d2, d5	40	29	25%	–	–
Jatoi, et al. [32]	54 (−/−)	PTX 200 mg/m2, 1 h, d1, 22; CBP AUC = 4, d1, 22; 5-Fu 225 mg/m2/d, civ, d1–42	45	21.2	35%	–	–

Abbreviations: SC squamous cell carcinoma, AC adenocarcinoma, pCR pathologic complete response, PTX paclitaxel, 5-FU 5-fluorouracil, DDP cisplatin, CBP carboplatin, AUC area under the curve